Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Bronchiectasis Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Bronchiectasis Overview | 8 | 1 |
| Bronchiectasis Therapeutics under Development by Companies | 9 | 1 |
| Bronchiectasis Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Bronchiectasis Products under Development by Companies | 13 | 1 |
| Bronchiectasis Companies Involved in Therapeutics Development | 14 | 10 |
| Alitair Pharmaceuticals, Inc. | 14 | 1 |
| Bayer AG | 15 | 1 |
| Grifols, S.A. | 16 | 1 |
| Insmed Incorporated | 17 | 1 |
| Kamada Ltd. | 18 | 1 |
| Polyphor Ltd. | 19 | 1 |
| Raptor Pharmaceutical Corp. | 20 | 1 |
| Recipharm AB | 21 | 1 |
| Savara Inc. | 22 | 1 |
| Vertex Pharmaceuticals Incorporated | 23 | 1 |
| Bronchiectasis Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 35 |
| alpha-1 proteinase inhibitor (human) second generation Drug Profile | 33 | 3 |
| amikacin sulfate Drug Profile | 36 | 9 |
| ARD-3150 Drug Profile | 45 | 5 |
| ciprofloxacin hydrochloride Drug Profile | 50 | 2 |
| doxofylline Drug Profile | 52 | 1 |
| erdosteine Drug Profile | 53 | 2 |
| Leukotriene-B4 Drug Profile | 55 | 1 |
| levofloxacin Drug Profile | 56 | 4 |
| POL-6014 Drug Profile | 60 | 2 |
| POL-7080 Drug Profile | 62 | 2 |
| vancomycin hydrochloride Drug Profile | 64 | 2 |
| VX-371 Drug Profile | 66 | 2 |
| Bronchiectasis Dormant Projects | 68 | 1 |
| Bronchiectasis Discontinued Products | 69 | 1 |
| Bronchiectasis Product Development Milestones | 70 | 13 |
| Featured News &Press Releases | 70 | 1 |
| Oct 18, 2016: Bayer to Present Data in Non-Cystic Fibrosis Bronchiectasis at the 2016 Annual Meeting of the American College of Chest Physicians | 70 | 1 |
| Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients | 70 | 1 |
| Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency | 71 | 1 |
| Mar 16, 2016: Raptor Announces Qualified Infectious Disease Product Designation for MP-376, Inhaled Levofloxacin | 72 | 1 |
| Jan 05, 2016: Aradigm to Host Corporate Update Conference Call on January 6 | 72 | 1 |
| Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis | 73 | 1 |
| Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) | 74 | 1 |
| Apr 16, 2015: Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City | 75 | 1 |
| Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia | 76 | 1 |
| Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation | 77 | 1 |
| Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm s Pulmaquin for Non-Cystic Fibrosis Bronchiectasis | 78 | 1 |
| Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) | 79 | 1 |
| Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis | 80 | 1 |
| May 20, 2014: FDA Grants QIDP Designation to Aradigm s Inhaled Antibiotic | 80 | 1 |
| Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA | 81 | 2 |
| Appendix | 83 | 2 |
| Methodology | 83 | 1 |
| Coverage | 83 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Expert Panel Validation | 83 | 1 |
| Contact Us | 83 | 1 |
| Disclaimer | 84 | 1 |